Leading UK Timber Processor and Packaging Manufacturer, James Jones & Sons Ltd., Adopts Intelligent Bio Solutions’ Fingerprint Drug Screening System Across its 25 Sites and 1,300 Employees
- None.
- None.
Insights
The adoption of Intelligent Fingerprinting's drug screening system by James Jones & Sons Ltd represents a strategic move in workplace safety and compliance. From a market research perspective, this deployment signals a growing trend in the adoption of innovative, non-invasive testing technologies within industrial settings. Considering the high-risk nature of James Jones' operations, the need for efficient and reliable drug testing is critical. The ease of use and rapid results provided by this system could potentially reduce downtime and enhance productivity, as traditional drug testing methods often require more time and can disrupt work processes.
Furthermore, as the system is rolled out across multiple locations, this could serve as a case study for other companies considering similar solutions. A successful implementation could lead to increased demand for Intelligent Bio Solutions' products, potentially affecting the company's market share and stock performance. The move towards in-house testing capabilities may also reflect a broader industry shift, where companies seek greater control over health and safety protocols, which could have implications for the occupational health testing market as a whole.
Intelligent Bio Solutions Inc.'s announcement of its partnership with James Jones & Sons Ltd could have a material impact on INBS's financial performance. By securing a contract with a significant UK employer, INBS is not only increasing its revenue streams but also diversifying its client base geographically and across industries. This move could be seen positively by investors, as it demonstrates the company's ability to penetrate new markets and the scalability of its technology.
The purchase of 11 drug screening systems, while not a large number in itself, is indicative of the potential for future sales growth, especially if the technology is adopted in other regions, such as James Jones' Australian operations. The direct sale of equipment combined with the consumable nature of the single-use cartridges presents a recurring revenue model that can be attractive from an investment standpoint. If the technology proves effective, it could lead to repeat orders and an expanded client base, which would have a favorable impact on the company's future earnings and stock valuation.
The implementation of Intelligent Fingerprinting's drug screening system within James Jones & Sons Ltd's operations is a proactive approach to workplace safety and legal compliance. In high-risk industries, employers have a legal obligation to ensure a safe working environment, which includes addressing substance misuse. By adopting a non-invasive, rapid testing method, James Jones & Sons Ltd is likely aiming to mitigate legal risks associated with workplace accidents that could be attributed to drug use.
Additionally, the introduction of an amnesty period before the policy's enforcement is a strategic decision that may help in minimizing potential legal challenges from employees. It also highlights the company's commitment to employee wellbeing rather than punitive measures. This approach could set a precedent for how other companies manage the balance between employee rights and safety requirements, potentially influencing future legal standards and employer policies within the industry.
Intelligent Fingerprinting to be used for in-house drug testing, enabling full testing control to support new James Jones drug and alcohol testing policy
Portable Intelligent Fingerprinting system easily covers testing needs across all remote locations and allows in-house ownership
NEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that leading UK timber processor and packaging manufacturer, James Jones & Sons Ltd is now using its revolutionary portable Intelligent Fingerprinting Drug Screening System that works by analyzing fingerprint sweat.
James Jones & Sons Ltd will use 11 readers deployed across the company’s 25 UK locations. The company will implement a random testing program for its 1,300 employees to proactively support its new substance misuse policy launched in November 2023.
Rosetta Forbes, Group Head of HR for James Jones & Sons Ltd, said, “James Jones has some 1,300 employees, many of whom operate high-risk machinery such as sawmill cutting equipment, pallet & packaging manufacturing units, and wood harvesting machinery. As an innovative company, we want to push our safety record forward, and Intelligent Fingerprinting will be central to our new substance misuse policy.”
“We are rolling out the Intelligent Fingerprinting Drug Screening System to provide in-house testing that will be available across all our sites, including our remote/rural operations, as required,” added Rosetta Forbes. “The system is a great match for our needs. It is easy for our HR and Health and Safety colleagues who are not medically trained to use. The system is non-invasive, fast, and cost-effective across our urban as well as remote locations, with easy sample collection that takes only seconds. On-site results for multiple drug groups in just ten minutes makes Intelligent Fingerprinting a very efficient and innovative solution for James Jones & Sons Ltd to adopt.”
James Jones & Sons Ltd’s in-house HR team will work collaboratively with their Health and Safety colleagues, as well as some local managers, who are all trained to use the sweat-based drug screening system to manage testing as required. The company has carefully planned the roll-out, incorporating a company-wide amnesty period that welcomes employees to approach the company for wellbeing support before the new policy came into force in December.
Harry Simeonidis, President and Chief Executive Officer of Intelligent Bio Solutions Inc., said, “For workplace testing, the Intelligent Fingerprinting Drug Screening System offers companies full control and the ability to drug test quickly, conveniently, and whenever needed. This enables organizations such as James Jones & Sons Ltd to be proactively responsible for the health and safety of its employees and customers while protecting its business reputation.”
James Jones has purchased 11 Intelligent Fingerprinting Drug Screening Systems consisting of portable DSR-Plus readers and single-use chain of custody sample collection cartridges. These will be located at the company's testing hubs that will geographically cover their 25 locations across the UK. The company’s Australian operations are also watching the deployment with a view to potentially expand the use of the system to that region.
An introductory video demonstrating fingerprint-based drug testing in action is available here.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company's biosensor platform has the potential to test for up to 130 indications, ranging from glucose to immunological conditions and communicable diseases. The Company's current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc/
About James Jones
James Jones & Sons Ltd is a 5th generation family business and one of the UK’s largest and most progressive timber processing companies with core activities in timber harvesting, sawmilling, pallets & packaging, and distribution. We operate from 25 sites across the UK, 11 Australian and 2 New Zealand sites, and employ over 2,100 people. In the UK, we operate seven sawmills throughout Scotland and the northeast of England: an engineered wood manufacturing plant in the north of Scotland and pallet and packaging operations at 14 sites across the UK. We produce high quality, British grown timber for the UK construction, landscaping, and agricultural sectors; market-leading JJI-Joists for the housebuilding and construction markets and pallets and packaging for blue chip domestic and exporting businesses. For further information on James Jones & Sons Ltd, visit: https://www.jamesjones.co.uk
Forward-Looking Statements:
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to develop and commercialize its diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
Media Contact:
Cheryl Billson
Comma Communications
cheryl.billson@commacomms.com
+44 (0)7791 720460
FAQ
What is the name of the company mentioned in the press release?
What is the new James Jones drug and alcohol testing policy?
How many readers will James Jones & Sons Ltd deploy for the drug testing system?
What is the purpose of the Intelligent Fingerprinting Drug Screening System?
What is the potential expansion plan for the system mentioned in the press release?
